How are patients’ preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn’s disease patients

Brunet-Houdard, Solène; Monmousseau, Fanny; Berthon, Geoffrey; Garets, Véronique Des; Laharie, David; Picon, Laurence; Fotsing, Ginette; Gargot, D.; Charpentier, C; Buisson, Anthony; Trang-Poisson, Caroline; Dib, Nina; Rüsch, Emmanuel; Aubourg, Alexandre

doi:10.1080/00365521.2022.2085057

Cited by 2 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in other studies, age was not a predictor for willingness to switch [ 15 , 24 ]. Contrary to intuition and a previous study by Brunet-Houdard et al [ 13 ], our results did not support the notion that patients with more severe illnesses or reduced quality of life might prefer IV treatment, potentially due to the additional interaction with healthcare professionals during infusions. Additionally, our hypothesis that individuals working full-time or who are unable to visit the infusion center independently would prefer SC treatment was not confirmed by our findings.…”

Section: Discussioncontrasting

confidence: 99%

“…They attributed this preference to their likely desire for proximity to a specialized healthcare professional, enabling them to comfortably address all their questions. Nevertheless, these patients dealing with diminished HRQoL showed a reluctance to allocate additional time for treatment, possibly due to fatigue and weariness [ 13 ]. In an Italian questionnaire study involving 311 IBD patients undergoing IV biological treatment, 49.8% of respondents indicated a preference for transitioning to SC therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Patient preferences are influenced by various factors, including cost [ 10 ] and the distance from the outpatient infusion facilities [ 13 ]. The Israeli health system, founded on a universal healthcare model, contains a “Health Basket”, which comprises a list of medications that are covered by national health insurance, ensuring access to essential pharmaceuticals.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Richter,

Cohen,

Kriger-Sharabi

et al. 2024

JCM

View full text Add to dashboard Cite

Biological inflammatory bowel disease (IBD) medications, once limited to intravenous (IV) administration, can now be administered both via IV and subcutaneously (SC). This study investigates patient preferences, willingness to switch from IV to SC, and associated factors. A questionnaire covering demographics, disease-related inquiries, quality of life, and IBD medication preferences was distributed via email, the Israeli Crohn’s Disease and Ulcerative Colitis Foundation, infusion centers, and clinics. From 454 IBD patients (median age: 42 years; 55.7% female), responses revealed a preference for SC every 8 weeks, which is comparable to daily oral dosing. Both options were significantly favored over IV every 8 weeks and SC every 2 weeks, with no statistically significant differences between the latter two. However, among patients who were experienced with both SC and IV administration, a clear preference for SC administration every 2 weeks over IV every 8 weeks surfaced. Among IV-treated patients, 54.5% resisted switching to SC. Key reasons for this included medical staff presence (57.7%), a fear of needles (46.4%), belief in infusion efficacy (37.1%), and longer intervals between infusions (36.1%). Findings suggest that transitioning from IV to SC treatment is challenging due to patient resistance, which is influenced by specific factors. Identifying and addressing these obstacles is crucial for optimizing IBD management.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Richter,

Cohen,

Kriger-Sharabi

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease

Noor

Sousa

Bettenworth

et al. 2023

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

There are now a growing number of licensed biological therapies for patients with Crohn’s disease. However, there can be significant costs associated with long-term maintenance treatment, as well as some concerns about potential side effects. As a result, there has been increasing interest in elective biological treatment discontinuation in selected patients, after a sustained period of remission. Following discontinuation, in cases of relapse, evidence to date has suggested that remission may often be regained by retreatment with the same biological agent. Therefore, a concept has emerged where cycles of biological therapy might be used. If this treatment strategy were to be applied in a subgroup of patients at low-risk of relapse, cycling might allow a substantial number of patients to have a lower, overall therapeutic burden – ensuring decreased exposure to biological therapy but still enabling appropriate disease control. Currently, there remains uncertainty about the benefit-risk balance for using cycles of biological treatment for patients with Crohn’s disease. Accordingly, an expert panel was convened by the European Crohn’s and Colitis Organisation (ECCO) to review the published literature and agree a series of consensus practice points. The panel aimed to provide evidence-based guidance on multiple aspects of biological treatment discontinuation and cycling, including the risk of relapse after elective treatment discontinuation, predictors of likely relapse or remission, safety, patient preferences and pharmacoeconomic aspects. Crucially, discussions about biological treatment discontinuation and cycling should be individualised, to enable shared decision-making by patients with their clinicians.

show abstract

How are patients’ preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn’s disease patients

Cited by 2 publications

References 48 publications

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease

Contact Info

Product

Resources

About